Top 5 Stocks to Buy Now
→ The Treasury just bought its own debt (From Golden Portfolio) (Ad)tc pixel Free TXG Stock Alerts

10x Genomics (TXG) Competitors

10x Genomics logo
$34.58 +2.71 (+8.50%)
Closing price 03:59 PM Eastern
Extended Trading
$34.44 -0.14 (-0.41%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TXG vs. PACB, RVTY, CAMT, BIO.B, and RAL

Should you buy 10x Genomics stock or one of its competitors? MarketBeat compares 10x Genomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 10x Genomics include Pacific Biosciences of California (PACB), Revvity (RVTY), Camtek (CAMT), Bio-Rad Laboratories (BIO.B), and Ralliant (RAL).

How does 10x Genomics compare to Pacific Biosciences of California?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

10x Genomics has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-3.55% -2.86% -2.23%
Pacific Biosciences of California -80.35%-571.06%-18.82%

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M6.83-$43.54M-$0.17N/A
Pacific Biosciences of California$160.01M2.80-$546.38M-$0.43N/A

10x Genomics presently has a consensus target price of $24.00, indicating a potential downside of 30.59%. Pacific Biosciences of California has a consensus target price of $1.83, indicating a potential upside of 27.31%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
Pacific Biosciences of California
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, 10x Genomics had 10 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 10 mentions for 10x Genomics and 0 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 1.50 beat 10x Genomics' score of 0.49 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company Overall Sentiment
10x Genomics Neutral
Pacific Biosciences of California Very Positive

Summary

10x Genomics beats Pacific Biosciences of California on 12 of the 15 factors compared between the two stocks.

How does 10x Genomics compare to Revvity?

Revvity (NYSE:RVTY) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revvity$2.86B4.14$241.20M$2.0950.65
10x Genomics$642.82M6.83-$43.54M-$0.17N/A

Revvity has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

Revvity has a net margin of 8.26% compared to 10x Genomics' net margin of -3.55%. Revvity's return on equity of 8.00% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Revvity8.26% 8.00% 4.83%
10x Genomics -3.55%-2.86%-2.23%

Revvity presently has a consensus target price of $107.73, suggesting a potential upside of 1.76%. 10x Genomics has a consensus target price of $24.00, suggesting a potential downside of 30.59%. Given Revvity's stronger consensus rating and higher probable upside, research analysts plainly believe Revvity is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revvity
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21
10x Genomics
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, 10x Genomics had 8 more articles in the media than Revvity. MarketBeat recorded 10 mentions for 10x Genomics and 2 mentions for Revvity. 10x Genomics' average media sentiment score of 0.49 beat Revvity's score of 0.47 indicating that 10x Genomics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revvity
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

86.7% of Revvity shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 8.8% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Revvity beats 10x Genomics on 9 of the 14 factors compared between the two stocks.

How does 10x Genomics compare to Camtek?

Camtek (NASDAQ:CAMT) and 10x Genomics (NASDAQ:TXG) are both mid-cap measuring and control equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Camtek presently has a consensus target price of $174.33, indicating a potential upside of 4.45%. 10x Genomics has a consensus target price of $24.00, indicating a potential downside of 30.59%. Given Camtek's stronger consensus rating and higher probable upside, analysts plainly believe Camtek is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Camtek
0 Sell rating(s)
7 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50
10x Genomics
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20

Camtek has a net margin of 9.63% compared to 10x Genomics' net margin of -3.55%. Camtek's return on equity of 22.26% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Camtek9.63% 22.26% 11.70%
10x Genomics -3.55%-2.86%-2.23%

In the previous week, 10x Genomics had 8 more articles in the media than Camtek. MarketBeat recorded 10 mentions for 10x Genomics and 2 mentions for Camtek. 10x Genomics' average media sentiment score of 0.49 beat Camtek's score of -0.06 indicating that 10x Genomics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Camtek
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Camtek has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Camtek, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Camtek$496.07M15.42$50.72M$0.87191.84
10x Genomics$642.82M6.83-$43.54M-$0.17N/A

Camtek has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

41.9% of Camtek shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 79.4% of Camtek shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Camtek beats 10x Genomics on 10 of the 15 factors compared between the two stocks.

How does 10x Genomics compare to Bio-Rad Laboratories?

10x Genomics (NASDAQ:TXG) and Bio-Rad Laboratories (NYSE:BIO.B) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

10x Genomics currently has a consensus price target of $24.00, suggesting a potential downside of 30.59%. Given 10x Genomics' stronger consensus rating and higher probable upside, equities research analysts clearly believe 10x Genomics is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, 10x Genomics had 10 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 10 mentions for 10x Genomics and 0 mentions for Bio-Rad Laboratories. 10x Genomics' average media sentiment score of 0.49 beat Bio-Rad Laboratories' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media.

Company Overall Sentiment
10x Genomics Neutral
Bio-Rad Laboratories Neutral

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bio-Rad Laboratories has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M6.83-$43.54M-$0.17N/A
Bio-Rad Laboratories$2.58B3.07$759.90M$6.0748.85

10x Genomics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Bio-Rad Laboratories has a net margin of 6.52% compared to 10x Genomics' net margin of -3.55%. Bio-Rad Laboratories' return on equity of 3.56% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-3.55% -2.86% -2.23%
Bio-Rad Laboratories 6.52%3.56%2.49%

Summary

10x Genomics beats Bio-Rad Laboratories on 8 of the 15 factors compared between the two stocks.

How does 10x Genomics compare to Ralliant?

10x Genomics (NASDAQ:TXG) and Ralliant (NYSE:RAL) are both mid-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, 10x Genomics had 9 more articles in the media than Ralliant. MarketBeat recorded 10 mentions for 10x Genomics and 1 mentions for Ralliant. 10x Genomics' average media sentiment score of 0.49 beat Ralliant's score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ralliant
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

84.7% of 10x Genomics shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 0.4% of Ralliant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

10x Genomics presently has a consensus price target of $24.00, suggesting a potential downside of 30.59%. Ralliant has a consensus price target of $69.00, suggesting a potential downside of 4.28%. Given Ralliant's stronger consensus rating and higher possible upside, analysts plainly believe Ralliant is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
1 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.20
Ralliant
1 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

10x Genomics has higher earnings, but lower revenue than Ralliant. 10x Genomics is trading at a lower price-to-earnings ratio than Ralliant, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$642.82M6.83-$43.54M-$0.17N/A
Ralliant$2.07B3.90-$1.22B-$10.94N/A

10x Genomics has a net margin of -3.55% compared to Ralliant's net margin of -58.55%. Ralliant's return on equity of 12.49% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-3.55% -2.86% -2.23%
Ralliant -58.55%12.49%6.40%

Summary

10x Genomics beats Ralliant on 8 of the 14 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TXG vs. The Competition

Export
Metric10x GenomicsMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$4.05B$1.60B$6.56B$12.24B
Dividend YieldN/AN/A2.69%5.82%
P/E RatioN/A78.4925.1723.98
Price / Sales6.8328.53553.76120.62
Price / CashN/A23.5044.8254.51
Price / Book5.545.2310.766.41
Net Income-$43.54M-$54.76M$3.56B$337.14M
7 Day Performance7.62%-0.88%1.37%-0.48%
1 Month Performance46.03%-3.51%0.81%0.49%
1 Year Performance217.53%-3.27%30.53%28.16%

10x Genomics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TXG
10x Genomics
1.8989 of 5 stars		$34.58
+8.5%		$24.00
-30.6%		+195.4%$4.05B$642.82MN/A1,240
PACB
Pacific Biosciences of California
2.8412 of 5 stars		$1.32
+0.8%		$1.83
+38.9%		+10.1%$406.89M$160.01MN/A730
RVTY
Revvity
2.5943 of 5 stars		$100.53
+0.9%		$107.73
+7.2%		+5.1%$11.12B$2.86B48.1011,000
CAMT
Camtek
2.0915 of 5 stars		$197.75
+2.3%		$174.33
-11.8%		+126.3%$8.86B$496.07M227.30400
BIO.B
Bio-Rad Laboratories
N/A$304.15
flat		N/A+16.0%$8.14B$2.58B50.118,200

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TXG) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
Firm That Predicted 2008, 2020, 2022: Right Now Looks Worse
The firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...
TradeSmith | Sponsoredtc pixel
VWAV: An Under-the-Radar Defense Play
VisionWave Holdings (NASDAQ: VWAV) is developing a multi-domain defense platform combining AI-powered analytic...
Equiscreen | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Man who predicted COVID 19 Crash warns of new crisis
A former CIA and Pentagon economic advisor predicted the 2008 financial crisis two years early - a warning so ...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Nearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...
Stansberry Research | Sponsoredtc pixel